Cargando…

Analysis of Cardiac Adverse Reactions Caused by Different Doses of Adriamycin Chemotherapy in Patients with Breast Cancer

PURPOSE: This paper is aimed at studying the adverse reactions of breast cancer patients after chemotherapy with different doses of adriamycin. METHODS: 122 breast cancer patients undergoing mastectomy in the Haining Central Hospital from June 2018 to June 2020 were selected as the research objects....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Guangwen, Wang, Daxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863445/ https://www.ncbi.nlm.nih.gov/pubmed/35211251 http://dx.doi.org/10.1155/2022/1642244

Ejemplares similares

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.
por: Carmo-Pereira, J., et al.
Publicado: (1987)

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients
por: Tadesse, Fikremariam Abiye, et al.
Publicado: (2023)

Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
por: Liu, Chang, et al.
Publicado: (2022)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer
por: Ren, Boxue, et al.
Publicado: (2019)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Modeling and Analysis of Breast Cancer with Adverse Reactions of Chemotherapy Treatment through Fractional Derivative
por: Tang, Tao-Qian, et al.
Publicado: (2022)

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
por: Javan-Noughabi, Javad, et al.
Publicado: (2018)

Acute Induction of Adriamycin‐resistance in Human Colon Carcinoma HT‐29 Cells Exposed to a Sublethal Dose of Adriamycin
por: Tomida, Akihiro, et al.
Publicado: (1995)

Identification of adriamycin resistance genes in breast cancer based on microarray data analysis
por: Chen, Yan, et al.
Publicado: (2020)

Artemether ameliorates adriamycin induced cardiac atrophy in mice
por: Weng, Wenci, et al.
Publicado: (2023)

Mucocutaneous Adverse Reactions of Cancer Chemotherapy and Chemoradiation
por: Naveed, Sheikh, et al.
Publicado: (2019)

Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin
por: Hayashino, Kenta, et al.
Publicado: (2022)

Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy
por: Moro, Kazuki, et al.
Publicado: (2022)

PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer
por: Chen, Yongxia, et al.
Publicado: (2021)

Different distribution of adriamycin in normal and leukaemic rats.
por: Sonneveld, P., et al.
Publicado: (1981)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis
por: Wang, Zhipeng, et al.
Publicado: (2015)

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
por: Cao, Bei, et al.
Publicado: (2013)

Dynamic Metabolic Response to Adriamycin-Induced Senescence in Breast Cancer Cells
por: You, Rong, et al.
Publicado: (2018)

Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report
por: Jang, Lee Chan, et al.
Publicado: (2019)

Global and Regional Longitudinal Strain Reduction in Breast Cancer Patients After First Chemotherapy Cycle With Fluorouracil, Adriamycin, and Cyclophosphamide Regimen
por: Astuti, Astri, et al.
Publicado: (2021)

IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis
por: Liao, Jian, et al.
Publicado: (2023)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
por: Barcelos, Flávia Campos, et al.
Publicado: (2019)

Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure.
por: Aitchison, R. G., et al.
Publicado: (1990)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells
por: XIE, XIAO-HONG, et al.
Publicado: (2014)

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.
por: Citro, G., et al.
Publicado: (1991)

CD155 downregulation synergizes with adriamycin to induce breast cancer cell apoptosis
por: Gao, Jian, et al.
Publicado: (2018)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer
por: Prieto-Callejero, Blanca, et al.
Publicado: (2020)

Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
por: Coldwell, Kate E., et al.
Publicado: (2008)

Diffuse Intrasinusoidal Hepatic Metastasis from Breast Cancer Presenting as Liver Failure: Effective and Rapid Treatment with Weekly Low-Dose Adriamycin
por: Afiat, Thanh-Phuong N., et al.
Publicado: (2020)

Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin
por: Qin, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45o7h76eq5ondhj4s5tatgdor0